CU23476A1 - ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL - Google Patents

ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL

Info

Publication number
CU23476A1
CU23476A1 CU20040020A CU20040020A CU23476A1 CU 23476 A1 CU23476 A1 CU 23476A1 CU 20040020 A CU20040020 A CU 20040020A CU 20040020 A CU20040020 A CU 20040020A CU 23476 A1 CU23476 A1 CU 23476A1
Authority
CU
Cuba
Prior art keywords
formulations
jojoba oil
emulsion
oleous
oil
Prior art date
Application number
CU20040020A
Other languages
Spanish (es)
Inventor
Lindblad Erik Bo
Martinto Anaiza Perez
Rubido Julio Cesar Aguilar
Nieto Gerardo Enrique Guillen
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040020A priority Critical patent/CU23476A1/en
Priority to ARP050100239A priority patent/AR047791A1/en
Priority to PCT/CU2005/000001 priority patent/WO2005072679A2/en
Publication of CU23476A1 publication Critical patent/CU23476A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente invención se describe el desarrollo de formulaciones oleosas agua en aceite o aceite en agua donde la fase oleosa está compuesta por el aceite de jojoba con el objetivo de favorecer un incremento en la respuesta inmune contra los antígenos administrados en las formulaciones que se describen. Estas nuevas formulaciones se obtienen a partir del uso del aceite de jojoba con uno o más surfactantes de alto y/o bajo contenido lipofílico en una emulsión con uno o más antígenos vacunales. Estas formulaciones son aplicables en la industria farmacéutica como formulaciones vacunales preventivas o terapéuticas.The present invention describes the development of oily formulations water in oil or oil in water where the oily phase is composed of jojoba oil in order to favor an increase in the immune response against the antigens administered in the formulations described . These new formulations are obtained from the use of jojoba oil with one or more high and / or low lipophilic surfactants in an emulsion with one or more vaccine antigens. These formulations are applicable in the pharmaceutical industry as preventive or therapeutic vaccine formulations.

CU20040020A 2004-01-29 2004-01-29 ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL CU23476A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU20040020A CU23476A1 (en) 2004-01-29 2004-01-29 ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL
ARP050100239A AR047791A1 (en) 2004-01-29 2005-01-24 ADJUTIVE FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL
PCT/CU2005/000001 WO2005072679A2 (en) 2004-01-29 2005-01-28 Adjuvant formulation containing an oily emulsion with jojoba oil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040020A CU23476A1 (en) 2004-01-29 2004-01-29 ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL

Publications (1)

Publication Number Publication Date
CU23476A1 true CU23476A1 (en) 2009-12-17

Family

ID=34812869

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040020A CU23476A1 (en) 2004-01-29 2004-01-29 ADJUSTMENT FORMULATION CONTAINING AN OLEOUS EMULSION WITH JOJOBA OIL

Country Status (3)

Country Link
AR (1) AR047791A1 (en)
CU (1) CU23476A1 (en)
WO (1) WO2005072679A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
EP0781559B1 (en) * 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
SE9900495D0 (en) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition

Also Published As

Publication number Publication date
AR047791A1 (en) 2006-02-22
WO2005072679A3 (en) 2006-03-16
WO2005072679A2 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
CO2022002685A2 (en) Enhanced Lipid Nanoparticles for Nucleic Acid Delivery
CL2018003452A1 (en) Semi-solid nasal and visual liquid cannabinoid formulations.
ES2539861T3 (en) Clevidipin emulsion formulations containing antimicrobial agents
BRPI0813092A8 (en) COMPOSITION OF OIL IN WATER EMULSION AND METHOD FOR PRODUCING IT.
MX2020012041A (en) Pharmaceutical formulation.
AR044050A1 (en) USE OF IVERMECTINE FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
MX2022007424A (en) Surfactants for use in healthcare products.
CL2017000829A1 (en) Pharmaceutical formulation comprising mixture of anti-alpha4beta7 antibody, a buffering agent, and citrate; use of said formulation to treat inflammatory bowel disease.
AR081542A1 (en) COMPOSITIONS OF PHARMACEUTICAL EMULSIONS WITH LOW OIL CONTENTS THAT UNDERSTAND A PROGESTAGEN
MX2007006561A (en) USE OF OMEGA-3 FATTY ACID (S) FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA CAUSED BY ANTIRRETROVIRAL TREATMENT OF PATIENTS INFECTED WITH HIV.
AR081535A1 (en) STABLE OLEOUS LIQUID FORMULATIONS READY TO USE, ITS PREPARATION AND USE
CO7101246A2 (en) Carbamate compound and preparation and use thereof
BR112012022797A2 (en) alcohol resistant pharmaceutical composition, and method for treating a disease with an alcohol resistant active agent formulation
CO6150191A2 (en) INFLUENZA VACCINE
EA200901161A1 (en) VACCINE AGAINST THE FLU IN THE FORM OF THE TYPE "OIL IN WATER" EMULSION
AR053360A1 (en) NEW FORMULATIONS OF VACCINES
MX2010002340A (en) Stable emulsion formulation hindering interaction across the water-oil interface.
CO6480980A2 (en) PHARMACEUTICAL COMPOSITION FOR A PROTEASE INHIBITOR OF HEPATITIS C VIRUS
PE20120584A1 (en) TRANSDERMAL PHARMACEUTICAL PREPARATIONS
UY31403A1 (en) "NOVEDOUS DERIVATIVES OF ({((3-Methylphenyl) -2H-TETRAZOL-5-IL) -ETOXI} -4H-1,2,4-TRIAZOL-3-IL), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICAL USE OF THE SAME" .
MX2021013285A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex.
ES2576740T3 (en) Topical pharmaceutical compositions that include REL-N- [6 - [(2R, 6S) -2,6-dimethyl-4-morpholinyl] -3-pyridinyl] -2-methyl-4 '- (trifluoromethoxy) - [1,1 '-biphenyl] -3-carboxamide
UY29085A1 (en) PIRIMIDINE DERIVATIVES 4-SULFONAMID SUBSTITUTED, INTERMEDIATE COMPOUNDS FOR PREPARATION, PREPARATION PROCEDURES, MEDICINAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
MX2023011701A (en) Pharmaceutical composition for controlled release of treprostinil.
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES